Aigen Investment Management LP Raises Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Aigen Investment Management LP lifted its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 20.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,000 shares of the company’s stock after acquiring an additional 670 shares during the quarter. Aigen Investment Management LP’s holdings in TransMedics Group were worth $249,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. New York State Teachers Retirement System acquired a new position in TransMedics Group during the 3rd quarter worth approximately $1,217,000. Farther Finance Advisors LLC boosted its stake in shares of TransMedics Group by 187.0% in the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after buying an additional 316 shares in the last quarter. Amalgamated Bank grew its holdings in TransMedics Group by 777.4% during the third quarter. Amalgamated Bank now owns 9,774 shares of the company’s stock worth $1,535,000 after acquiring an additional 8,660 shares during the period. Principal Financial Group Inc. raised its position in TransMedics Group by 260.1% in the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after acquiring an additional 146,115 shares in the last quarter. Finally, Montanaro Asset Management Ltd lifted its holdings in TransMedics Group by 12.5% in the third quarter. Montanaro Asset Management Ltd now owns 117,235 shares of the company’s stock valued at $18,364,000 after acquiring an additional 12,985 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on TMDX shares. Robert W. Baird lowered their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. Canaccord Genuity Group lowered their target price on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $75.00 price target (down from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research note on Wednesday, February 5th. Finally, TD Cowen dropped their price objective on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $67.46 on Monday. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The business has a fifty day moving average of $68.30 and a 200-day moving average of $97.19. The stock has a market cap of $2.27 billion, a price-to-earnings ratio of 71.77 and a beta of 2.12.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.